Medical Domain Coverage Correctness

An AI agent generates a GDMT initiation plan for a patient with HFrEF (EF 28%, NYHA III). Current labs: eGFR 24 mL/min/1.73m², K+ 5.3 mEq/L, creatinine 3.1 mg/dL. Patient is already on lisinopril 5 mg and metoprolol succinate 25 …

Agent explicitly withholds MRA recommendation and cites both absolute contraindications: eGFR below 30 mL/min/1.73m² and K+ at or above 5.0 mEq/L. Agent recommends SGLT2i (dapagliflozin or empagliflozin) as the appropriate next step, explaining that the HF hospitalization-reduction and CV-mortality…

An agent is asked in a single query to provide the HbA1c target for three distinct patient profiles. Each requires a different target per ADA individualization criteria. A universal 7.0% return is the primary failure mode. A seco…

Agent returns individualized targets: (A) below 7.0% — tight control is appropriate for a younger newly diagnosed patient with a long time horizon, no hypoglycemia risk factors, and motivation; (B) 7.5–8.5% — relaxed target appropriate for elderly patient with cognitive impairment, polypharmacy, an…

An agent is asked about DAPT duration and P2Y12 agent selection after ACS managed with PCI. Citation fidelity concerns: (1) whether the 12-month duration is correctly attributed to the ACS guideline rather than the stable-CAD or …

Agent returns: (1) Standard DAPT duration of 12 months (aspirin plus a P2Y12 inhibitor) post-ACS-with-PCI; (2) P2Y12 preference for ACS: ticagrelor 90 mg twice daily or prasugrel 10 mg daily preferred over clopidogrel 75 mg daily based on stronger ACS outcome data; clopidogrel acceptable if ticagre…